Article
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Pharmacogenetics - 1 Aug 1996
Sullivan-Klose T H, Ghanayem B I, Bell D A, Zhang Z Y, Kaminsky L S, Shenfield G M, Miners J O, Birkett D J, Goldstein J A
Abstract excerpt
Tolbutamide undergoes hydroxylation in humans via a cytochrome P450-mediated pathway. The primary P450 isozyme responsible for this metabolism is thought to be CYP2C9. Population studies have indicated the existence of slow metabolizers of tolbutamide (approximately 1 in 500) suggesting a rare polymorphism associated with 2C9. Several allelic variants of 2C9 have been identified; however, the effect of these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.